[1] 许俊堂,胡大一.华法林的临床应用[J].中国医刊,2004;39:43-46. [2] 蒋文平,朱骏,戚文航,等.如何对待心房颤动[J].中华心血管病杂志,2003,31 (7) :483-486. [3] 胡大一,孙艺红,周自强,等.中国人非瓣膜性心房颤动脑卒中危险因素的病例-对照研究[J].中华内科杂志,2003,42(3):157. [4] 张鹤平,胡大一.非心瓣膜疾病性心房颤动与血栓栓塞[J].中华心血管病杂志,2005,33(10):966. [5] 马长生,周玉杰,马煜,等.北京地区非瓣膜病心房颤动患者缺血性脑卒中发生率及影响因素的随访研究[J].中华心血管病杂志 ,2002,30:1651. [6] 胡大一,张鹤萍,孙艺红,等.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J] .中华心血管病杂志 ,2006,34 (4) :295–298. [7] Hirsh J, Dalen J, Anderson D R, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest , 2001 ,119 (1 Suppl ) :8S-21S. [8] 陆慰萱.抗凝药物与肺血栓栓塞症的临床应用评价[J]. 中国医院用药评价与分析,2003,3(2):71-74. [9] Tham LS, Goh BC, Nafziger A, et al. A warfarin dosing model Asians thatuse ingle-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9[J].Clin Phamacol Ther,2006,80(4):346. [10] Sconce EA, Khan TI, Wynne HA, et al .The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen[J].Blood,2005,106:2329-2333. [11] 孙艺红,胡大一.华法林对中国人心房颤动患者抗栓的安全性和有效性研究[J]. 中华内科杂志,2004,43 (4 ):258-260. [12] Fihn SD,McDonell M,Martin D,et al.Risk fsctors for complications of chronic anticongulation:A multicenter study[J].An Med,1993,118:511-520. [13] Chan TY. Interaction between warfarin and danshen (Salvia m iltiorriza)[J]. Ann Pharmacother, 2001, 35(4):501-504. [14] 柳亚敏,邵蓉,葛卫红.美国抗凝治疗临床组织及其运行方式[J].中外健康文摘, 2008, 3(1):681. |